Latest Asia Pacific News

Integrated Research Limited reported an 18% revenue decline and a 51% drop in net profit for FY25, while unveiling a strategic pivot towards AI-driven product innovation and cloud services.

CleanSpace Holdings posted a robust 26% revenue increase in FY25, turning the corner to positive EBITDA and cash flow in the second half, driven by strong industrial market demand and operational efficiencies.

Kip McGrath Education Centres Limited reported modest revenue growth and a solid increase in EBITDA for FY25, despite a significant net loss driven by its exit from the US market. The company declared a fully franked final dividend, signaling confidence in its refocused core business.

Chrysos Corporation reported a robust FY25 with 46% revenue growth and an 80% jump in EBITDA, driven by expanding adoption of its PhotonAssay technology and a landmark contract with gold giant Newmont. The company projects further growth in FY26 with revenue guidance of $80-90 million.

CleanSpace Holdings Limited reported a 26% increase in revenue to $19.8 million for FY25, alongside a significant reduction in net loss to $478,276. The company’s strategic expansion and innovation efforts underpin its improving financial health and global market presence.

Austin Engineering reported a robust 22.2% revenue increase in FY25, driven by a strong North American expansion and improved margins in Asia Pacific. Despite some operational challenges in Chile, the company’s underlying profits soared, setting a confident tone for FY26.

Web Travel Group signals strong momentum heading into FY26, projecting record EBITDA and a robust $3.1 billion in first-half Total Transaction Value despite geopolitical headwinds.

WebBeds reported a 22% rise in Total Transaction Value to nearly $5 billion for FY25, while EBITDA fell 14% amid margin pressures and higher costs. The company is targeting $10 billion TTV by FY30 with improved profitability.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Regal Partners Limited reported robust half-year results for 1H25, with funds under management reaching $17.7 billion and normalised net profit after tax hitting $44.8 million. The firm achieved record net inflows and maintained a strong balance sheet, signaling continued growth momentum.

LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.

Data#3 Limited reported a robust FY25 with $3 billion in gross sales and an 11.4% rise in net profit before tax, underpinned by cloud, security, and AI demand. The company’s FY26 strategy focuses on customer experience and operational excellence amid evolving IT sector trends.